Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mayumi Uesugi is active.

Publication


Featured researches published by Mayumi Uesugi.


Bioorganic & Medicinal Chemistry Letters | 1996

A novel class of antagonists for metabotropic glutamate receptors, 7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylates

Hirokazu Annoura; Atsuko Fukunaga; Mayumi Uesugi; Toshio Tatsuoka; Yoshiko Horikawa

7-(Hydroxyimino)cyclopropa[b]chromen-la-carboxylates (4a-c), highly potent antagonists for a phospholipase C-linked metabotropic glutamate receptor, mGluR1, were synthesized through cyclopropanation onto 4-oxo-4H-1-benzopyran-2-carboxylates (5a-c) utilizing dimethyloxosulfonium methylid followed by treatment with hydroxylamine.


Bioorganic & Medicinal Chemistry | 2002

Synthesis and biological evaluation of new 4-arylpiperidines and 4-aryl-4-piperidinols: dual Na+ and Ca2+ channel blockers with reduced affinity for dopamine D2 receptors

Hirokazu Annoura; Kyoko Nakanishi; Mayumi Uesugi; Atsuko Fukunaga; Seiichi Imajo; Atsuko Miyajima; Yoshiko Tamura-Horikawa; Shigeki Tamura

Abstract A series of novel 4-arylpiperidines and 4-aryl-4-piperidinols ( 2a – f , 3a – f and 4a – f ) was synthesized and evaluated for blocking effects on both neuronal Na + and T-type Ca 2+ channels and binding affinity for dopamine D 2 receptors. Most of the compounds blockaded both ion channels with potency greater than or equal to flunarizine 1a which was adopted as a reference standard. In addition, these compounds had significantly reduced affinity for dopamine D 2 receptors which is common in this class of structure. Compounds 2a – f , 3a – f and 4a – f exhibited potent anticonvulsant effects following systemic (ip) administration on audiogenic seizures in DBA/2 mice, indicating their excellent brain permeability. The neuroprotective activity of 2a , 3a and 4a was also assessed in a transient middle cerebral artery occlusion (MCAO) model. These compounds significantly reduced neuronal damage without affecting ischemic hyperthemia, while flunarizine 1a produced only minor reductions. In particular, 4a had 1.7-fold the potency in this MCAO model but only 1/20 the affinity for dopamine D 2 receptors of 1a . The superposition of 2a , 3a and 4a on the basis of analyses of systematic conformation and similar structure has revealed that the cinnamyl, phenacyl and phenoxypropanol groups are likely to be structurally and biologically equivalent. Moreover, the superposition of 2a and 2f shows that diphenyl ether and biphenyl groups occupy a similar space, suggesting that both groups act as a bioisostere for the blockade of ion channels; however, this is not the case for dopamine D 2 receptors since only biphenyl compounds such as 2f had high affinity similar to flunarizine 1a . Compound 4a (SUN N5030) has a good pharmacological profile and may be useful in the alleviation and treatment of ischemic diseases.


Bioorganic & Medicinal Chemistry Letters | 1999

A novel class of Na+ and Ca2+ channel dual blockers with highly potent anti-ischemic effects

Hirokazu Annoura; Kyoko Nakanishi; Mayumi Uesugi; Atsuko Fukunaga; Atsuko Miyajima; Yoshiko Tamura-Horikawa; Shigeki Tamura

A series of novel arylpiperidines (4a-d) which have highly potent blocking effects for both neuronal Na+ and T-type Ca2+ channels with extremely low affinity for dopamine D2 receptors were synthesized. Among these compounds, 1-(2-hydroxy-3-phenoxy)propyl-4-(4-phenoxyphenyl)-piperidine hydrochloride (4c; SUN N5030) exhibited remarkable neuroprotective activity in a transient middle cerebral artery occlusion (MCAO) model.


Archive | 1996

Ameliorant or remedy for symptoms caused by ischemic diseases and compounds useful therefor

Hirokazu Annoura; Mayumi Uesugi; Shinsuke Matsuki; Atsuko Fukunaga; Toshio Tatsuoka; Shigeki Tamura; Norio Inomata


Archive | 1996

Medicament for the alleviation or treatment of symptom derived from ischemic disease and compound useful therefor

Hirokazu Annoura; Mayumi Uesugi; Shinsuke Matsuki; Atsuko Fukunaga; Toshio Tatsuoka; Shigeki Tamura; Norio Inomata


Archive | 1996

Arylpiperidine and arylpiperazine derivatives and drugs containing the same

Hirokazu Annoura; Mayumi Uesugi; Atsuko Fukunaga; Shigeki Nara-shi Tamura


Archive | 1996

Arylpiperidine and arylpiperazine derivatives and medicament containing the same

Hirokazu Annoura; Mayumi Uesugi; Atsuko Fukunaga; Shigeki Tamura


Archive | 1996

Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen Symtomen improvement or cure of diseases caused by ischemic diseases and used therefor phenylpiperidinverbingungen

Hirokazu Annoura; Atsuko Fukunaga; Norio Inomata; Shinsuke Matsuki; Shigeki Tamura; Toshio Tatsuoka; Mayumi Uesugi


Archive | 1996

Improvement or cure of diseases caused by ischemic diseases and symtomen used therefor phenylpiperidinverbingungen

Hirokazu Annoura; Atsuko Fukunaga; Norio Inomata; Shinsuke Matsuki; Shigeki Tamura; Toshio Tatsuoka; Mayumi Uesugi


Archive | 1996

ALIVIO O REMEDIO PARA SINTOMAS CAUSADOS POR ENFERMEDADES ISQUEMICAS Y COMPUESTOS DE FENILPIPERIDINA UTILIZADOS PARA ELLO.

Hirokazu Annoura; Atsuko Fukunaga; Norio Inomata; Shinsuke Matsuki; Shigeki Tamura; Toshio Tatsuoka; Mayumi Uesugi

Collaboration


Dive into the Mayumi Uesugi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge